Controlled trial – Page 25 – Communicable Diseases Research

Evaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial

중등도 또는 중증 COVID-19 환자에 대한 표준 치료와 함께 흡입 황산마그네슘의 효능 및 안전성 평가: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-182022-09-10
Journal: Trials [Category] 임상,

Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered A single-center, retrospective, observational study

중국 동북부 7개 도시에서 완전히 회복된 COVID-19 환자 55명에 대한 의료 치료 단일 센터, 후향적, 관찰 연구

Observational Study

Published on 2021-01-152022-09-10
Journal: Medicine [Category] 임상, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered administration Antibiotics antiviral drug antiviral drugs antiviral therapy benefit caused China Clinical outcome clinical outcomes Co-infection collected Controlled trial controlled trials coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demographics double-blind drug early administration effective emerging disease glucocorticoid Glucocorticoids immunomodulators Intervention Laboratory Linezolid Lopinavir Lopinavir/ritonavir lopinavir/ritonavir) median medical treatment medication Mild mild symptoms moxifloxacin observational study Patient patients with COVID-19 reduce respiratory retrospective risk Ritonavir SARS-CoV-2 Seven severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe group severe symptoms single-center Symptoms the disease transferred treat treated Treatment umifenovir
[DOI] 10.1097/MD.0000000000023923 PMC 바로가기 [Article Type] Observational Study

Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial

글루코코르티코이드(CORTIVID)를 사용한 COVID-19 폐렴의 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-112022-09-10
Journal: Trials [Category] 임상, 치료기술,

[키워드] absolute difference active cancer Admission age allergy ambient approved arterial blood Barcelona baseline biochemical Blinding Block randomisation block size Blood Breastfeeding C-reactive protein C-reactive protein (CRP candidate clinical Clinical outcome clinical outcomes clinical trial contraindication Control control group Controlled trial COVID-19 COVID-19 admission COVID-19 pneumonia criteria death decrease defined detect Deterioration Device diabete Diabetes Mellitus diagnosis of SARS-CoV-2 discretion dissemination drug drug treatment early treatment Effectiveness element elevated eligible emergency room ethics committee EudraCT exclusion criteria expected explained ferritin Follow-up followed by following glucocorticoid Glucocorticoids groups hospital Hospital admission hypertension ICU Identifier IL-6 immunosuppressants IMPROVE inclusion criteria independent Infection inflammatory biomarkers Informed consent intensive care intensive care unit interleukin interleukin-6 Intervention intervention group intravenous intravenous infusion Laboratory Loading dose Lopinavir Lopinavir/ritonavir maintenance dose management manic manic disorder mechanical ventilation Medical devices Medicine Medicines Methylprednisolone Nasopharyngeal swab nasopharyngeal swabs number objective outcome outcome assessor outcome assessors Outpatient oxygen oxygen saturation PaO parallel-group partial pressure Partial pressure of oxygen participant Patient patient age patients patients with COVID-19 Pharmacy Placebo Pneumonia polymerase chain Potential Pregnancy primary endpoint Primary outcome procalcitonin proportion protocol Psychiatric Psychological psychotic pulse Pulses Quadruple blind radiological random randomisation randomised randomised controlled trial randomizeR receive recommendation recruit recruitment Registered Remdesivir required researcher reverse transcriptase Reverse transcriptase polymerase chain reaction Ritonavir RT-PCR Sample size SARS-CoV-2 SARS-CoV-2 pneumonia sequence Spain Spanish sputum Standard of care status stratified study outcomes Study protocol supplementary material Symptom Tablet the patient therapy title total sample size transcriptase Treatment treatment failure Trial Trial registration two group two groups two-tailed type I type II error uncontrolled hypertension unit university Version website with COVID-19
[DOI] 10.1186/s13063-020-04999-4 PMC 바로가기 [Article Type] Letter

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Randomized Controlled Trial

Published on 2021-01-092022-10-04
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상,

[키워드] 1:1 95% CI acute respiratory syndrome adjusted age analysed Analysis assigned AstraZeneca AZD1222 blinded both group Brazil calculated ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Clinical research clinical trials Coalition Cohort contribute control group Controlled trial coronavirus Coverage COVID-19 COVID-19 pandemic Cutoff death dose doses Efficacy efficacy analysis enrolled evaluated event finding first dose Follow-up foundation funding hospitalised include Innovation Interaction interim analysis IQR ISRCTN89951424 low dose median Melinda Gate network NIHR nucleic acid amplification occurred Older Oxford participant Participants Poisson regression model randomised randomised controlled trial Randomly Registered risk robust Safe Safety safety profile SARS-CoV-2 second dose seronegative participant severe adverse event severe COVID-19 South South Africa Standard dose subset Swab symptomatic Telle Treatment Trial trials Vaccine vaccine efficacy Valley viral particle
[DOI] 10.1016/S0140-6736(20)32661-1 PMC 바로가기 [Article Type] Randomized Controlled Trial

Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial

일반 인구에서 SARS-CoV-2 감시를 위한 4가지 다른 전략의 효과 및 비용 효율성(CoV-Surv 연구): 클러스터 무작위 2인자 통제 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-082022-09-01
Journal: Trials [Category] MERS, 임상, 진단, 치료기술, 치료제,

[키워드] acceptability Active surveillance activities activity addition Admission age analyzed applicability applied approach Arm ARMS Asymptomatic Asymptomatic carrier Asymptomatic carriers Asymptomatic case Asymptomatic cases best Blinding caused choice clinical clinical symptom Clinical symptoms close contact Cluster cluster-randomised controlled trial Complete completion component conducted Controlled trial Cost effectiveness cost-effectiveness Course COVID-19 defined detection rate determine determined by diagnosed Diagnosis dialectic Disease surveillance dissemination effective Effectiveness element eligible estimate estimates evaluated expected False positives finding followed by Gender General population generate Germany gold gold standard Health healthy hospital household identify implementation include individual individuals infected individual infected individuals Infection information isothermal amplification Laboratory limit Local local public health lockdowns Loop-mediated isothermal amplification mail men and women MONITOR municipality objective Older outbreak outcome pandemic parameter parameters participant Perception Perspective population surveillance population-based surveillance positive positive sample PPS Precision predict preference preferences Prevalence Prevent Primary outcomes Probability prognostic model protocol qPCR Quantitative questionnaire random Random sample randomisation Randomly real time receive Region Registered rejection representing required response rates resulting risk RT-LAMP Saliva saliva samples Sample Sample size sample sizes SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 pandemic SARS-CoV-2 surveillance SARS-CoV-2 testing SARS-CoV-2 tests Satisfaction screened second secondary Secondary outcomes selected Sensitivity and specificity Spread status Strategy study participant Study participants study participation Study protocol Surveillance Symptom symptomatic test result tested the SARS-CoV-2 threshold Total total sample size Trial Trial registration variety virus website while
[DOI] 10.1186/s13063-020-04982-z PMC 바로가기 [Article Type] Letter

Rehabilitation Exercise and psycholoGical support After covid-19 InfectioN’ (REGAIN): a structured summary of a study protocol for a randomised controlled trial

재활 운동 및 심리적 지원 After covid-19 Infection'(REGAIN): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-062022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 age allocation concealment anticipated anxiety symptoms assessment automatically baseline Bengali best blind Blinding Care clinical clinically Cognitive function Complete computer-generated Controlled trial COVID-19 COVID-19 infection Critical care current death defined depressive determine dissemination Dyspnoea eight element email engage Engagement English exclusion criteria exercise Group allocation Health health economic evaluation health problems hospital hospital care hospital discharge include Informed consent life mental health mental health problem mental health problems NHS number objective Online outcome parallel group participant performed physical physical activity Physical health Post-traumatic stress disorder Practitioner Primary outcome profile protocol psychological support PTSD Quality of life questionnaire randomisation randomised randomised controlled trial rehabilitation Rehabilitation Exercise reported resource Sample size secondary Secondary outcomes sequence Standard status stratified Study protocol Support supported symptom severity Treatment Urdu usual care utility ventilatory ventilatory support Version web-based system website
[DOI] 10.1186/s13063-020-04978-9 PMC 바로가기 [Article Type] Letter

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs

COVID-19에 대한 무작위 대조 시험: 최적의 무작위화 방법론 평가 - 완료된 시험의 데이터 검증 및 진행 중인 및 미래의 무작위 시험 설계 개선 필요

Review

Published on 2021-01-012022-09-11
Journal: International journal of antimicrobial agents [Category] 임상,

[키워드] (coronavirus disease 2019 benefit Controlled trial coronavirus disease Coronavirus disease 2019 COVID-19 Dexamethasone disease severity group Guidance HCQ Health Organization high mortality hospitalised COVID-19 patient Hydroxychloroquine IMPROVE Lopinavir Lopinavir/ritonavir methodology Metrics Mortality NIH Ordinal Scale outcomes pandemic patients randomisation randomised controlled trial Randomised trial RCT RCTs recovery RECOVERY trial reduced Remdesivir risk reduction Ritonavir sampling errors seven-point ordinal scale severity solidarity the disease Time to recovery treat Treatment Trial trials utilised WHO World Health Organization
[DOI] 10.1016/j.ijantimicag.2020.106222 PMC 바로가기 [Article Type] Review

Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial

COVID-19 치료를 위한 아르테미시닌-피페라퀸의 안전성 및 효능: 공개, 비무작위 및 대조 시험

Controlled Clinical Trial

Published on 2021-01-012022-09-11
Journal: International journal of antimicrobial agents [Category] SARS, 임상, 치료법, 치료제,

[키워드] 95% CI 95% confidence interval adverse events antimalarial Artemisinin both groups change changes Computed tomography control group Controlled trial coronavirus coronavirus disease coronavirus disease-2019 COVID-19 effective therapy Efficacy enrolled group laboratory parameter Mean ± standard deviation Mild Mild-to-moderate Open-label participant Patient percentage percentages physician Piperaquine Primary outcome QT interval respiratory Safety SARS-CoV-2 Secondary outcomes Severe acute respiratory syndrome severe acute respiratory syndrome-coronavirus-2 significantly shorter Standard deviation Treatment two groups undetectable Viral Viral RNA
[DOI] 10.1016/j.ijantimicag.2020.106216 PMC 바로가기 [Article Type] Controlled Clinical Trial

Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information

정보 손실 없이 코로나바이러스 질병 2019 시험에서 이기종 종점 조화

Article

Published on 2021-01-012022-09-11
Journal: Critical Care Medicine [Category] 임상, 치료제,

[키워드] categories category clinical trial clinical trials Clinicians contribute Controlled trial controlled trials core coronavirus disease Coronavirus disease 2019 Course death Descriptive analysis develop discharge Effect Endpoint endpoints event Follow-up health authorities Health Organization heterogeneous Hospital stay Hospitalization include information Loss majority measure measurement mechanical ventilation multiplicity on mechanical ventilation outcome parameter Patient positive individuals primary analysis Probability provide public health authorities Randomized controlled trial Randomized controlled trials reconstructed Registered regulatory agencies statistical statistical analysis Statistical analysis plan Support the patient Treatment treatment effect treatment effects Trial trials while World Health Organization
[DOI] 10.1097/CCM.0000000000004741 PMC 바로가기 [Article Type] Article